The World's Most Clinically-Relevant Preclinical Model.
Our Organoid 2.0 (ALI-PDO™) platform is the first to preserve the native tumor microenvironment at scale, providing an unprecedented window into human cancer biology.
Not All Organoids Are Created Equal.
Feature
Conventional 2D Cell Lines
PDO 1.0 (Standard Organoids)
OrgaNova ALI-PDO™ 2.0
Microenvironment
Absent
Partial (Tumor cells only)
Fully Preserved (Tumor + Stromal + Immune)
Immune Component
Absent
Absent
Native, Functional Immune Cells (>80% retention)
Clinical Prediction Rate
10–30%
40–60%
65–93% (avg. 84.43%)
Applications
Basic screening
Drug sensitivity
I-O, ADC, Cell Therapy, Biomarker Discovery, Functional Genomics
Format
2D monolayer
Matrigel-embedded
Air-Liquid Interface (ALI), 96/384-well compatible
Culture Stability
Weeks
2–4 weeks
>30 days (up to 200 days demonstrated)